company background image
IPIX

Innovation Pharmaceuticals OTCPK:IPIX Stock Report

Last Price

US$0.033

Market Cap

US$16.8m

7D

-1.8%

1Y

-84.4%

Updated

01 Oct, 2022

Data

Company Financials
IPIX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

IPIX Stock Overview

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.

Innovation Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Innovation Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.033
52 Week HighUS$0.54
52 Week LowUS$0.019
Beta0.16
1 Month Change-17.33%
3 Month Change4.70%
1 Year Change-84.39%
3 Year Change-69.44%
5 Year Change-95.24%
Change since IPO-72.17%

Recent News & Updates

Shareholder Returns

IPIXUS BiotechsUS Market
7D-1.8%0.4%-2.5%
1Y-84.4%-25.6%-23.2%

Return vs Industry: IPIX underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: IPIX underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is IPIX's price volatile compared to industry and market?
IPIX volatility
IPIX Average Weekly Movement14.4%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: IPIX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: IPIX's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20054Leo Ehrlichhttps://www.ipharminc.com

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer.

Innovation Pharmaceuticals Fundamentals Summary

How do Innovation Pharmaceuticals's earnings and revenue compare to its market cap?
IPIX fundamental statistics
Market CapUS$16.83m
Earnings (TTM)-US$7.04m
Revenue (TTM)US$18.00k

1,113x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPIX income statement (TTM)
RevenueUS$18.00k
Cost of RevenueUS$0
Gross ProfitUS$18.00k
Other ExpensesUS$7.06m
Earnings-US$7.04m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin100.00%
Net Profit Margin-39,116.67%
Debt/Equity Ratio21.9%

How did IPIX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IPIX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPIX?

Other financial metrics that can be useful for relative valuation.

IPIX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue795x
Enterprise Value/EBITDA-2.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does IPIX's PB Ratio compare to its peers?

IPIX PB Ratio vs Peers
The above table shows the PB ratio for IPIX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.7x
ONVO Organovo Holdings
0.6xn/aUS$17.9m
SNGX Soligenix
4.5x-11.8%US$18.8m
EDSA Edesa Biotech
1.2x68.9%US$14.2m
APTX Aptinyx
0.4x-0.7%US$24.9m
IPIX Innovation Pharmaceuticals
3.6xn/aUS$16.8m

Price-To-Book vs Peers: IPIX is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (1.7x).


Price to Earnings Ratio vs Industry

How does IPIX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: IPIX is expensive based on its Price-To-Book Ratio (3.6x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is IPIX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPIX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IPIX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IPIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IPIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPIX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Innovation Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovation Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of IPIX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Innovation Pharmaceuticals's filings and announcements here.

Past Performance

How has Innovation Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


13.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IPIX is currently unprofitable.

Growing Profit Margin: IPIX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPIX is unprofitable, but has reduced losses over the past 5 years at a rate of 13.4% per year.

Accelerating Growth: Unable to compare IPIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: IPIX has a negative Return on Equity (-148.86%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Innovation Pharmaceuticals's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IPIX's short term assets ($4.0M) do not cover its short term liabilities ($4.8M).

Long Term Liabilities: IPIX's short term assets ($4.0M) exceed its long term liabilities ($841.0K).


Debt to Equity History and Analysis

Debt Level: IPIX has more cash than its total debt.

Reducing Debt: IPIX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPIX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IPIX has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.5% each year.


Discover healthy companies

Dividend

What is Innovation Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Innovation Pharmaceuticals Dividend Yield vs Market
How does Innovation Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Innovation Pharmaceuticals)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Innovation Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate IPIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPIX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IPIX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.1yrs

Average management tenure


CEO

Leo Ehrlich (64 yo)

14.83yrs

Tenure

US$515,850

Compensation

Mr. Leo Ehrlich, CPA serves as Chairman at Innovation Pharmaceuticals Inc. He has been the Chief Executive Officer and Chief Financial Officer of Innovation Pharmaceuticals Inc. (previously known as Cellce...


CEO Compensation Analysis

Leo Ehrlich's Compensation vs Innovation Pharmaceuticals Earnings
How has Leo Ehrlich's remuneration changed compared to Innovation Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021n/an/a

-US$10m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021US$516kUS$466k

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020n/an/a

-US$10m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020US$545kUS$466k

-US$7m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019n/an/a

-US$7m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019US$466kUS$466k

-US$9m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$13m

Sep 30 2018n/an/a

-US$14m

Jun 30 2018US$466kUS$466k

-US$16m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017n/an/a

-US$18m

Sep 30 2017n/an/a

-US$17m

Jun 30 2017US$466kUS$466k

-US$16m

Mar 31 2017n/an/a

-US$14m

Dec 31 2016n/an/a

-US$13m

Sep 30 2016n/an/a

-US$13m

Jun 30 2016US$466kUS$466k

-US$13m

Compensation vs Market: Leo's total compensation ($USD515.85K) is below average for companies of similar size in the US market ($USD774.31K).

Compensation vs Earnings: Leo's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IPIX's management team is seasoned and experienced (7.1 years average tenure).


Board Members

Experienced Board: IPIX's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of IPIX?
Owner TypeNumber of SharesOwnership Percentage
Institutions16,1500.003%
Individual Insiders19,705,5614.0%
Private Companies45,032,6599.1%
General Public428,238,17386.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.


Top Shareholders

Top 7 shareholders own 13.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.13%
Kips Bay Select LP
45,032,659$1.5m112.42%no data
3.73%
Leo Ehrlich
18,393,773$614.4k0%no data
0.15%
Barry Schechter
750,000$25.1k0%no data
0.11%
Zorik Spektor
525,000$17.5k0%no data
0.0075%
Jane Harness
36,788$1.2k0%no data
0.0022%
Kingfisher Capital, LLC
11,000$367.40%no data
0.001%
CapFinancial Partners, LLC, Asset Management Arm
5,150$172.00%no data

Company Information

Innovation Pharmaceuticals Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Innovation Pharmaceuticals Inc.
  • Ticker: IPIX
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$16.829m
  • Shares outstanding: 503.87m
  • Website: https://www.ipharminc.com

Number of Employees


Location

  • Innovation Pharmaceuticals Inc.
  • 301 Edgewater Place
  • Suite 100
  • Wakefield
  • Massachusetts
  • 1880
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPIXOTCPK (Pink Sheets LLC)YesClass A Common StockUSUSDApr 2007

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.